PreveCeutical Medical, Inc. | Crystal Equity Research Report

CER Focus Reports are published by Crystal Equity Research, an alternative resource for company-specific research on small- capitalization companies in selected industries. Our mission at Crystal Equity Research is to provide our investing clients with alpha-generating analysis of a company's investment potential. We offer a non-consensus examination of financial performance as well as value-creating due diligence on recent events and the company's competitive position. The work of Crystal Equity Research, LLC is guided by the Code of Ethics and Standards of Professional Conduct set by the Char- tered Financial Analyst Institute. We adhere to the Best Practices Guidelines Governing Analyst/Corporate Issuer Relations adopted by the CFAI and the National Investor Relations Institute. New York, New York Disclaimer: Any opinions expressed in this publication are statements of judgment at the publication date and are subject to change without notice. Information contained herein comes from independent sources believed reliable, but accuracy is not guaranteed. This publication is not an offer or solicitation to buy or sell any securi- ties. This publication does not address specific investment objectives, financial situations or particular needs of any recipient. The information herein is provided for general information purposes only and should not be con- sidered an individualized recommendation. The security or industry discussed in this report may not be suitable for all investors. All investments involve risk. All recipients are encouraged to use multiple sources of investment information and to actively monitor their holdings. Investors may review information concerning the profiled companies available at the web sites of the U.S. Securities and Exchange Commission (SEC) and the Financial Industry Regulatory Authority (FINRA). Additional information on investment newsletters and Internet stock fraud is also available from the SEC and FINRA . Disclosures: Neither Crystal Equity Research nor any of its employees or affiliates have a beneficial interest in the securities of the company profiled in this publication unless otherwise specifically disclosed here. No employee or affiliate of Crystal Equity Research serves on the board of directors of the company profiled in this publication. Crystal Equity Research does not provide investment banking or advisory services and has not provided such services to the company profiled in this publication. Crystal Equity Research received compensation for coverage of the company profiled in this publication. The CER Focus Report subscription fee of $7,500 was paid in cash in advance by PreveCeutical Medical Holdings. Phone: 212-400-7519 E-mail: Illuminating investment opportunities in small capitalization companies…. DISCLAIMER AND DISCLOSURES Copyright © 2008-2018 Crystal Equity Research Page 11